Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study

Table 5 Stratified analysis for change in total WOMAC score based on baseline COMP levels

COMP (ng/mL)	Analytical method	Type of analysis	Time point (Days)	Placebo (n = 27)	GC (n = 28)	UC-II (n = 27)	p value (95 % CI)
COMP (ng/mL)	Analytical method	Type of analysis	Time point (Days)	Placebo (n = 27)	GC (n = 28)	UC-II (n = 27)	Overall^a	GC vs PBO	UC-II vs PBO	UC-II vs GC
≥285	ANCOVA	mITT	180	−368 ± 41.7	−396 ± 40.9	−574 ± 41.6	0.002	0.88 (−168 to 112)	0.002^b (−347 to −65)	0.009^c (−317 to −38)
	MMRM	mITT	180	−351 ± 44.1	−398 ± 41.1	−540 ± 44.2	0.006	0.71 (−188 to 94)	0.006^b (−330 to −48)	0.048^c (−282 to −1)
	iAUC^d	ITT	1 to 180	−1351 ± 212	−1582 ± 204	−2384 ± 207	0.003	0.72 (−934 to 473)	0.002^b (−1741 to −325)	0.02^c (−1498 to −107)
				(n = 26)	(n = 29)	(n = 26)
<285	ANCOVA	mITT	180	−463 ± 38.8	−508 ± 36.6	−526 ± 38.7	0.48	0.67 (−173 to 82)	0.49 (−195 to 68)	0.94 (−145 to 109)
	MMRM	mITT	180	−442 ± 38.2	−493 ± 37.3	−521 ± 38.1	0.34	0.60 (−178 to 76)	0.32 (−208 to 50)	0.86 (−155 to 100)
	iAUC^e	ITT	1 to 180	−1626 ± 185	−1908 ± 178	−1902 ± 185	0.49	0.52 (−896 to 333)	0.55 (−902 to 350)	0.99 (−607 to 618)

Values presented as Mean ± SE
^aOverall p value was obtained by comparing the mean changes among the three groups using ANCOVA
^bSignificant difference between the UC-II and the placebo groups using Tukey-Kramer test
^cSignificant difference between the UC-II and the GC groups using Tukey-Kramer test
^dNumber of subjects used for analyses, 27, placebo; 29, GC; 28, UC-II
^eNumber of subjects used for analyses, 27, placebo; 29, GC; 27, UC-II

ISSN: 1475-2891